O-1602

O-1602 is a synthetic small molecule and an analog of abnormal cannabidiol, structurally related to cannabinoids but distinct from classical cannabinoid drugs such as THC. It acts as a potent agonist at the GPR55 receptor (EC50 ≈ 13 nM) and also activates GPR18, while showing negligible affinity for the classical cannabinoid receptors CB1 and CB2. O-1602 induces activation of RhoA, cdc42, and rac1 signaling pathways. It increases proliferation of neural stem cells in vitro and in vivo, promotes neurogenesis in animal models, exhibits anti-inflammatory effects (notably reducing IL-6 and TNF-alpha), reduces tumor growth in preclinical cancer models (including paclitaxel-resistant breast cancer), stimulates food intake/adiposity in rodents, shows analgesic properties without sedation or psychoactive effects typical of cannabinoids, and has been investigated for potential use in bladder diseases such as detrusor overactivity[1][2][5][6][7][8].

Other names

Abn-CBDOAbnormal CannabidiorcinAbnormal CannabidiorcinolAbnormal Cannabiorcodiol